Hemodialysis patients present more morbidity and mortality risk in coronavirus disease 2019. In patients who may develop severe symptoms the process called “viral sepsis” seems to be a crucial mechanism. In those cases, the hemodialysis procedure provides an excellent tool to explore the benefit of some extracorporeal therapies.
We reported the outcome of 4 hemodialysis patients with severe COVID-19 treated with Seraph100 hemoperfusion device. Three of four cases presented a good clinical response after hemoperfusion.
In conclusion, the treatment with Seraph100 device may be a simultaneous treatment to improve the hemodialysis patients with severe SARS-CoV-2.